Menu
Company reaffirms its commitment to information security and data protection in healthcare technology
Boston, US and Rolle, Switzerland – January 9, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced it has successfully achieved ISO/IEC 27017:2015 and ISO/IEC 27018:2019 certifications for information security and privacy protection in its cloud services from BSI, the business improvement and standards company. It has also achieved recertification to ISO/IEC 27001:2022. The Company first achieved its ISO/IEC 27001 certification in 2014, demonstrating a robust information security management system was implemented to handle customer data securely.
These internationally recognized standards, developed and published by the world’s most recognized standards organization for information security management systems, underscore the Company’s commitment to maintaining the highest standards of security and data protection for its customers and the patients they serve.
SOPHiA GENETICS has consistently prioritized the security of customer data and privacy of the patients they serve for over a decade, ensuring the highest level of data security for the 780 healthcare institutions it serves globally.
By achieving two new certifications, SOPHiA GENETICS further solidifies its commitment to protecting the data of its customers and complying with global data protection regulations. The certifications highlight the Company’s commitment to proactively aligning with the evolving cybersecurity landscape. In addition, customers can be reassured by SOPHiA GENETICS’ role in establishing privacy, transparency, and regulatory compliance as top priorities that are consistently held to the highest standard.
“We are raising the bar for how cloud-based health data should be managed and protected,” said Daan van Well, Chief Legal and Regulatory Officer of SOPHiA GENETICS. “These certifications showcase our dual commitment: implementing best practices in collaboration with our partners and offering secure, trustworthy services to our customers at the same time. This achievement reinforces our longstanding commitment to data protection and cloud security and further solidify our position as leaders in cloud security and data privacy in the health data space.”
ISO standards are widely recognized internationally as the gold standard to ensure the security of the broader public. To demonstrate the quality of its focus on advanced security standards, SOPHiA GENETICS underwent a rigorous evaluation from BSI (British Standards Institution), a third-party auditor, to obtain the ISO certificates.
David Mudd, Global Head of Digital Trust, Assurance at BSI said: “Digital healthcare offers an immeasurable opportunity for society, but to truly unlock the potential of this, patients and clinicians need to be able to trust the technology is safe, secure and reliable. Achieving these certifications from BSI demonstrates SOPHiA GENETICS’ commitment to its customers to deliver reliable and accurate insights while ensuring any data processed by its technology is secure. Their customers and stakeholders can have the confidence that they are working with an organization dedicated to the highest standards and level of care when it comes to information security and data privacy in the cloud.”
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
Leading community-based practice to utilize increased set of solid tumor applications
Boston, MA and Rolle, Switzerland, November 21, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research.
Tennessee Oncology started using SOPHiA GENETICS in early 2024, when it began to validate the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™ alongside the SOPHiA DDM™ Hereditary Cancer Solution. As the practice worked with SOPHiA GENETICS throughout the year, it experienced the benefits of utilizing the SOPHiA DDM™ Platform for its next generation sequencing (NGS) testing and today announced it will begin to validate the SOPHiA DDM™ RNAtarget Technology and the SOPHiA DDM™ for Comprehensive Genomic Profiling (CGP) application.
“In our time using SOPHiA DDM™, we have been impressed with the outstanding results and incredible support, allowing us to retain our samples in-house and stay abreast of changing guidelines. The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology.
The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end workflow, allowing for a faster turnaround time and consolidating testing to save sample material. By combining RNA sequencing, CGP, and liquid biopsy testing,SOPHiA DDM™ delivers a comprehensive molecular view of cancer, improving a broader understanding of cancer biology for research that can help to improve future clinical decision-making and treatment planning for complex cancer cases.
“We are excited to expand our support of Tennessee Oncology and its network of oncology practices that are driving the future of community-based cancer care, especially as they bring these sophisticated tests to often underserved communities," said John Carey, Managing Director, NORAM, SOPHiA GENETICS. "By furthering their research and providing access to advanced cancer testing, Tennessee Oncology is innovating the cancer landscape and improving outcomes for patients in need.”
For more information on how labs can benefit from SOPHiA’s end-to-end workflows across a multitude of applications, visit SOPHiAGENETICS.com, or connect on LinkedIn. For more information on Tennessee Oncology, visit tnoncology.com, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
About Tennessee Oncology:
Tennessee Oncology, one of the nation’s largest community-based cancer care practices, is home to one of the leading clinical trial networks in the country. Established 1976 in Nashville, Tennessee Oncology’s mission remains unchanged: To provide access to high-quality cancer care and the expertise of clinical research for all patients, at convenient locations within their community and close to their home. Our growing network of physicians and locations is based on this mission. For more information, visit www.tnoncology.com.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
Launch of new application enables global access to highly recognized solid tumor profiling assay
Boston, MA and Rolle, Switzerland [November 20, 2024] - SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency.
“The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine,” said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. “Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with MSK. Launching this application is a powerful step in our vision to decentralize access to advanced tumor profiling technologies, making these capabilities more widely available, especially in underserved populations.”
Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of Pathology and Lab Medicine at MSK, added, “We share a vision with SOPHiA GENETICS to advance precision medicine and to make our leading tests more accessible to patients around the world.”
Through MSK-IMPACT® powered with SOPHiA DDM™, organizations can process more precise oncology analysis by enhancing the accuracy of somatic mutation detection, including in genes that are highly relevant for the current pharmaceutical industry R&D pipelines, such as MTAP. The matched tumor-normal analysis approach allows clinicians and researchers to detect somatic mutations more confidently, minimizing the risk of misclassifying germline variants as tumor-specific. Additionally, institutions benefit from the global collective intelligence created by SOPHiA GENETICS’ network, allowing users to contribute to and draw from a continuously evolving base of real-world data and insights from diverse populations.
SOFIVA GENOMICS, a leading molecular diagnostics company in Taiwan, is among the first to adopt this application. The company initially partnered with SOPHiA GENETICS in 2022 to utilize the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Now, SOFIVA GENOMICS is expanding its tumor profiling capabilities by adding MSK-IMPACT® powered with SOPHiA DDM™ alongside the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.
Chia-Cheng Hung, General Manager, SOFIVA GENOMICS, commented, “Our partnership with SOPHiA GENETICS has greatly enhanced our ability to provide localized, highly accurate genomic testing. Access to this advanced technology enables us to bring advanced, trusted capabilities and further our progress on cancer research in Taiwan.”
MSK-IMPACT® powered with SOPHiA DDM™ enables a more efficient workflow, with the entire process from DNA extraction to final report taking approximately five days. Clinicians and researchers benefit from access to OncoKB™, MSK’s Precision Oncology Knowledge Base, which further enhances the interpretive power of the SOPHiA DDM™ analysis through data-driven, actionable insights. In-house analytical validation results for MSK-IMPACT® powered with SOPHiA DDM™ showed high concordance to the single-site MSK-IMPACT® test, achieving:
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. Concordance results based on analytic assessment of RUO products.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
BOSTON and ROLLE, Switzerland, November 6, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic Intelligence Platform into SOPHiA GENETICS’ Alamut™ Visual Plus, to empower researchers and clinical geneticists with a solution that helps accelerate variant interpretation for rare disorders.
Time is crucial in gathering actionable insights for rare diseases and cancers due to the complexity and unknown elements of their genetic underpinnings. Identifying these variants often involves navigating limited literature and sparse data, as many rare disorders lack comprehensive studies. Delays in finding relevant information can hinder accurate analysis and interpretation of genomic variants. Many rare conditions have no cure, and easy access to relevant, comprehensive and well-organized information can help accelerate insights and health decisions.
Alamut™ Visual Plus is an advanced decision-support tool for the exploration, annotation, and interpretation of genetic variants from next-generation sequencing (NGS) data. Genomenon’s Mastermind® Genomic Intelligence Platform provides comprehensive curated evidence for genomic data, as well an indexed content from more than 10 million full-text articles. The integration of the two tools significantly enhances variant curation and interpretation by connecting the Alamut™ Visual Plus comprehensive, full genome browser for variant interpretation to a vast library of scientific research, offering critical insights even for rare variants with limited existing research. This partnership will prove especially valuable in such cases where findings from only a single study globally might be available that hold the key to understanding a variant’s pathogenicity. By offering immediate access to a broad spectrum of indexed data and curated genomic insights, researchers and clinicians can more efficiently assess the pathogenicity of variants, enabling them to make informed decisions with greater confidence.
“We are excited to expand our work with Genomenon and provide our customers the opportunity to access world-class tools like Mastermind® through our technology platform.” said Ross Muken, President, SOPHiA GENETICS. “This partnership simultaneously benefits our customers, who will gain a more comprehensive understanding of detected variants in a seamless, single platform, while providing Genomenon the opportunity to broaden its reach through our unmatched global network.”
“Collaborating with SOPHiA GENETICS allows us to provide geneticists and researchers with the most comprehensive and up-to-date genomic research available as they review patient data in Alamut,” said Mike Klein, CEO of Genomenon. “The links to Mastermind® from Alamut will put curated genomic data and the most recent research on every variant at the fingertips of clinicians assure patient diagnoses are informed by the most recent scientific findings in a single, complete workflow.”
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
About Genomenon
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development. For more information, visit GENOMENON.COM
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
SOPHiA GENETICS Media Contact:
Kelly Katapodis
[email protected]
BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer (“CFO”) and Chief Operating Officer (“COO”), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company’s new CFO.
In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS’s global business operations and work even more closely on strategic planning with CEO, Jurgi Camblong. He will continue to lead the company’s go-to-market function, including Clinical sales, BioPharma Dx sales, sales support, marketing, customer experience, and operations. Ross joined SOPHiA GENETICS in February 2021 as CFO and was appointed as CFO and COO in March 2023.
“I want to congratulate Ross on his well-deserved promotion to President,” said Jurgi Camblong, SOPHiA GENETICS CEO and Co-Founder. “Ross has been an instrumental part of our success since he joined almost four years ago, first as CFO and more recently as COO. I am grateful for his trusted partnership in positioning SOPHiA GENETICS for long-term growth.”
Jurgi Camblong adds, ““I am also delighted to welcome George Cardoza to our executive leadership team. George is a proven business leader and brings a wealth of deep financial expertise, leadership experience, and industry knowledge to SOPHiA GENETICS. As we continue to grow, George is uniquely qualified to help us succeed in this next exciting chapter of our journey. The leadership of both Ross and George will be crucial as we continue to further enhance our operational effectiveness while also balancing our need to consistently innovate.”
As CFO, Cardoza will oversee all corporate finance functions, including accounting, financial planning and analysis (“FP&A”), investor relations, internal audit, tax, and treasury.
Mr. Cardoza brings more than 30 years of experience in the precision medicine and clinical diagnostics industry, with extensive experience in both financial and operational leadership. Before joining SOPHiA GENETICS, he was the CFO and Head of Service Delivery at Biocartis, a molecular diagnostics company. Prior, he spent over twelve years with NeoGenomics Laboratories in several executive roles (CFO, President Pharma Services Division, and President and Chief Operating Officer Laboratory Operations), and previously spent more than fourteen years with Quest Diagnostics in various roles including Controller of the Central Region.
Throughout his career, Cardoza has shown a strong talent for financial management, strategic planning, and driving businesses towards increasing levels of performance. He has a deep understanding of the industry landscape and a proven track record of success in executing and influencing growth-oriented business strategies. Mr. Cardoza holds a B.S. in Finance and Accounting from Syracuse University and an MBA from Michigan State University.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
Investor Contact:
Kellen Sanger
Media Contact:
Kelly Katapodis
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy.
Boston, MA and Rolle, Switzerland, September 14, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.
The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment.
The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care.
"Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This study harnesses the power of multimodal data and advanced AI to identify which patients are most likely to benefit from specific therapies. By tailoring treatment strategies based on a patient's unique multimodal profile, we aim to improve outcomes and offer new hope to those battling this difficult disease."
The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
###
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials.
Boston, MA and Rolle, Switzerland, September 12, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
The details of the presentations are as follows:
Title: Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Poster Session: New Diagnostic Tools, Poster #1198
Date/Time: Sunday, September 15, 2024, 17h20 CEST
Presenting Author: Julien Pontis, Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS
This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been developed as a clinical trial assay for Boundless Bio’s ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.
“ecDNA-enabled cancers have a unique biology, with a growing body of research showing these tumors rapidly evolve and typically fail to respond to targeted therapies, leading to worse patient prognoses, including poor time to progression and overall survival. We have developed and validated a proprietary algorithm to detect ecDNA from the outputs of NGS panels routinely used to detect alterations in patient tumors that can be used to select patients for clinical trials,” said Julien Pontis, Technical Product Manager and Lead Data Scientist at SOPHiA GENETICS.
Title: TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Poster Session: NSCLC, Metastatic, Poster #1325
Date/Time: Saturday, September 14, 2024, 12h00 CEST
Presenting Author: Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center
This poster will feature the TRIDENT study, which leverages machine learning to develop multimodal signatures that can identify patients who would benefit most from the addition of tremelimumab to the durvalumab and chemotherapy regimen in the context of first-line treatment of stage IV non-small cell lung cancer. Dr. Ferdinandos Skoulidis from the University of Texas MD Anderson Cancer Center will present the findings, which are based on a retrospective multimodal analysis of the POSEIDON Phase 3 trial.
Abstracts for these posters are available on the conference website.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
###
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
The global collective intelligence network aims to accelerate precision oncology research and care.
Boston, US, and Rolle, Switzerland, September 12, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutions to fuel the next wave of innovation in oncology by making real-world data available for research.
SOPHiA UNITY, the pioneering initiative by SOPHiA GENETICS, harnesses multimodal data and analytics to drive innovation from a global network. The bar for innovation in oncology is increasing as indications become more fragmented, more complex and requiring larger datasets. No single institution can address this challenge alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this challenge, harmonizing high-quality, diverse, multimodal data at scale, leveraging the collective intelligence of leading research institutions.
Exactis Innovation in Montreal, Quebec, Canada, an organization of hospital partners dedicated to improving cancer survivorship through real-world data, as well as Institut Paoli-Calmettes in Marseille, France, one of the largest cancer centers in France, will be joining SOPHiA UNITY. In addition, Gemelli Hospital in Rome, Italy, named the best hospital in Italy in 2024, has expressed interest in joining the collaborative.
These organizations accompany inaugural member Memorial Sloan Kettering Cancer Center, a top cancer treatment and research institution. The SOPHiA UNITY network includes three countries and over 100,000 committed patient profiles with multimodal data.
“By uniting a critical mass of data and expertise through SOPHiA UNITY, we are empowering a global network of top-tier institutions to leverage real-world data to tackle the complexities of cancer. This initiative provides a new opportunity to advance oncology research with one of the most robust sources of diverse data available in the market to drive breakthroughs and improve patient outcomes worldwide," said Jurgi Camblong, PhD, Co-founder and CEO of SOPHiA GENETICS. "Together, we have the power to change the world."
Members benefit from participating in innovative global projects funded by industry and have access to the SOPHiA GENETICS AI-driven technology that increases efficiency of data curation, structuring and harmonization efforts. Collaborations made possible by SOPHiA UNITY pave the way for continued advancement of oncology research and data-driven medicine.
Members of SOPHiA UNITY can use SOPHiA CarePath™ which provides large-scale data insights from various modalities—including imaging, genomics, and pathology, as well as clinical notes and a diverse array of patient profiles. Data are safely and anonymously collected, harmonized and curated using SOPHiA GENETICS’ advanced AI-based technology and proprietary algorithms, delivering meaningful, data-driven insights.
For more information visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months.
BOSTON and ROLLE, Switzerland, September 10, 2024– SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ to 20 locations worldwide over the next 12 months.
Liquid biopsy testing offers a complementary alternative to solid tumor testing, which is not always feasible due to insufficient tissue, low quality tissue, or the invasiveness of the procedure. The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making.
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of the highly validated liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution. The solution combines the sophisticated analytics, state-of-the-art algorithms, and decentralized, cloud-based offerings of the SOPHiA DDM™ Platform, with the scientific and clinical expertise of MSK in cancer genomics to provide a best-in-class liquid biopsy solution.
By increasing availability of MSK-ACCESS® powered with SOPHiA DDM™, SOPHiA GENETICS and AstraZeneca aim to understand how liquid biopsy testing can complement solid tissue testing, and in some cases, provide greater benefit for labs and patients. This understanding will help support the case for broad global implementation. Additionally, through a dedicated real-world evidence study, researchers will be able to evaluate the operational benefits of liquid biopsy testing, including the speed of results and the ability of users to consistently achieve high-quality data in a variety of laboratory settings.
“Our collaboration with AstraZeneca has the potential to dramatically accelerate global access to liquid biopsy testing, especially in underserved populations, which in turn could contribute to reshaping diagnostics, treatment, and monitoring of cancer cases throughout the world. Their support is instrumental to making this improved access a reality,” said Philippe Menu, M.D., Ph.D, Chief Medical and Chief Product Officer, SOPHiA GENETICS. “Additionally, the breadth and depth of real-world data that we will generate through the implementation of this decentralized liquid biopsy testing platform on a global scale will be unprecedented, providing novel avenues to accelerating cancer research.”
Since launching MSK-ACCESS powered with SOPHiA DDM™ in April 2024, a first wave of 14 leading healthcare institutions worldwide have signed on to piloting and adopting the application. These institutions include renowned cancer centers and reference laboratories such as:
BioReference® and Tennessee Oncology in the U.S.; Oncohelix in Canada; Dasa in Brazil; Universitätsklinikum Heidelberg in Germany; Stavanger University Hospital in Norway; IUCT Oncopole in France; Synnovis and South West Genomic Laboratory Hub, operating out of North Bristol NHS Trust in the U.K.; Sofiva Genomics in Taiwan; Syndicate Bio in Nigeria; A.O.U. Senese in Italy; and Karkinos Healthcare and Strand Life Sciences in India.
The partnership with AstraZeneca will further catalyze the adoption of MSK-ACCESS® powered with SOPHiA DDM™.
As more hospitals and labs go into routine, SOPHiA GENETICS and AstraZeneca, in collaboration with leading cancer institutes within the SOPHiA GENETICS community, will generate a vast set of real-world data from patients around the world with a variety of cancers. This data set has the potential to generate unique insights towards advancing cancer research and drug development.
“We are deeply committed to bringing liquid biopsy expertise to labs and institutions throughout the globe at an expedited pace, and are confident this rollout will further support access to testing and aid in providing data-driven treatment options to patients around the world,” said Kristina Rodnikova, Head of Global Oncology Diagnostics, AstraZeneca.
The deployment of MSK-ACCESS® powered with SOPHiA DDM™ was announced in October 2023 as part of a collaboration between SOPHiA GENETICS, AstraZeneca and MSK. Together, the three companies are working to combat global health inequities and advance cancer research.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
###
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
Boston, US, and Rolle, Switzerland, September 7, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care.
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure.
The ELBS primarily focuses on liquid biopsy testing for cancer, which aligns with the work that SOPHiA GENETICS has done to increase access to this sophisticated testing. SOPHiA GENETICS decentralized MSK-ACCESS®, the highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK), so customers in Europe and worldwide have access to a best-in-class liquid biopsy solution.
“ELBS facilitates scientific exchange, clinical studies, and networking between leading experts, and we are thrilled to have SOPHiA GENETICS bring their global expertise and insights to our dynamic network of partners as we advance the field of liquid biopsy,” said Dr. Klaus Pantel, Founder and Chairman of the ELBS.
“We are impressed by the expansive community that the ELBS has created and are looking forward to collaborating with the ELBS to move this groundbreaking field forward to further widespread adoption and reimbursement for liquid biopsy testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “We believe that our participation will bring best-in-class technology and key learnings from our global community to complement and enhance the work of the ELBS moving forward.”
The ELBS network currently consists of more than 87 member institutions including academic institutions and university hospitals, as well as industry partners spread across biotech, device manufacturers, diagnostic companies, standard providers and pharmaceutical companies. Several members of the society, such as IUCT-Oncopole, work with SOPHiA GENETICS for liquid biopsy testing.
“We are pleased to welcome SOPHiA GENETICS to the European Liquid Biopsy Society. As the first laboratory in France and first European Liquid Biopsy member to adopt the MSK-ACCESS® powered with SOPHiA DDM™ application, we have experienced firsthand the technical expertise of the team at SOPHiA GENETICS combined with the analytical power of the SOPHiA DDM™ Platform to produce high-quality, meaningful insights for our teams. We are looking forward to continuing to further the field of liquid biopsy while serving our patients alongside the SOPHiA GENETICS team,” said a representative of the biology laboratory of medical oncology from IUCT-Oncopole in Toulouse.
###
About European Liquid Biopsy Society
The European Liquid Biopsy Society” Network was developed from the EU IMI “CANCER-ID” project (2015-2019) to further strengthen the field of Liquid Biopsy. The ELBS combines domestic and international orientation and promotes exchange between academic, industrial and clinical sectors as well as the health care system.
The network is further intended to promote the development of standardized guidelines and training in the field of “Liquid Biopsy” for physicians and researchers in related disciplines. The network, including third parties, also launches public relations campaigns on the subject of “Liquid Biopsy”, for example by sponsoring symposiums, presentations and press releases.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.